Valeda PBM

Photobiomodulation (PBM) is the first approved treatment by the United States Food & Drug Administration (FDA) for patients with dry age-related degeneration (AMD) to improve vision. PBM uses specific light wavelengths to improve retinal cell function. The Valeda® Light Delivery System (Valeda) delivers multiwavelength PBM treatment across three wavelengths that target distinct cellular targets to improve overall retinal health and disease outcomes. Our physicians are excited that a non-invasive treatment for dry AMD is now available.

The FDA authorization of Valeda reflects an extensive review of clinical trial data, including safety, efficacy, and the robustness of the study results, all of which support the positive utility of this treatment for patients with dry AMD.

Multiple trials have assessed Valeda’s safety and effectiveness. At Month 24, approximately 64% of PBM-treated eyes responded with significant vision gain, of which 20% could see approximately two lines better on the standard eye chart! The trial also noted additional benefits, including reduced disease progression and improved quality of life. Further, the treatment was very safe and required nothing invasive, such as injections, medications, dilation, or surgery!

Valeda is an in-office treatment device that requires 9 treatments over a 3-week period, three times a year. Each treatment takes less than 5 minutes per eye and is painless and easy!

If you are interested, make an appointment today to ask our eye care providers if you are a good candidate.

For more information, please visit: Valeda™ PBM Photobiomodulation for Dry AMD | Alcon Professional